Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Updated CLL guidelines

Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398

Major changes or additions to new guidelines for chronic lymphocytic leukemia include the following:

Molecular genetics: Recognition of the clinical importance of specific genomic alterations/mutations 17p deletion and mutations in TP53 on therapeutic response.

IGHV mutational status: Immunoglobulin variable heavy chain (IGHV) genes offer important prognostic information.

Biomarkers: Soluble CD23, thymidine kinase, and beta-2-microglobulin need to be standardized and used in prospective clinical trials.

MRD: Minimal residual disease should be assessed in clinical trials aimed at maximizing remission depth.

Antiviral prophylaxis: Patients should be tested for HBV serological status before starting on an anti-CD20 agent.

Read the article.

Citation:

Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in CLL

Uninterrupted ibrutinib with CAR T may boost outcomes in CLL , Gauthier J et al. ASH 2018, Abstract 299

The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018

Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

First-line ibrutinib has long-term survival benefit, Barr PM et al. Haematologica. 2018;103(9):1502-10.